Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis
- PMID: 3489062
- PMCID: PMC2188384
- DOI: 10.1084/jem.164.3.814
Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis
Abstract
In vitro culture of human peripheral blood lymphocytes in IL-2 results in the generation of cytotoxic cells that can lyse fresh and cultured solid tumor cells, as well as hematopoietic tumor cell lines, without deliberate immunization or MHC restriction. This has been referred to as the lymphokine activated killer (LAK) phenomenon. Here, we show that the majority of this activity is mediated by NK cells that express the Leu-19 (NKH-1) antigen, but do not express CD3. The precursor of this effector population also expressed the phenotype CD3-, Leu-19+. Peripheral blood CD3+ T lymphocytes contributed little to the LAK phenomenon, although low levels of non-MHC restricted cytotoxicity against hematopoietic tumor cell targets were mediated by a subset of CD3+ T lymphocytes that coexpressed the Leu-19 antigen. These studies clearly indicated that the LAK phenomenon is not mediated by a unique LAK cell, but is mediated mainly by IL-2-activated peripheral blood NK cells.
Similar articles
-
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.J Exp Med. 1982 Jun 1;155(6):1823-41. doi: 10.1084/jem.155.6.1823. J Exp Med. 1982. PMID: 6176669 Free PMC article.
-
Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.J Exp Med. 1983 Mar 1;157(3):884-97. doi: 10.1084/jem.157.3.884. J Exp Med. 1983. PMID: 6601174 Free PMC article.
-
Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.Cancer Res. 1988 Apr 15;48(8):2184-92. Cancer Res. 1988. PMID: 3258186
-
Antigenic, functional, and molecular genetic studies of human natural killer cells and cytotoxic T lymphocytes not restricted by the major histocompatibility complex.Fed Proc. 1986 Nov;45(12):2823-8. Fed Proc. 1986. PMID: 3095151 Review.
-
[Identification and characterization of effector lymphocytes lysing autologous tumor cells].Gan To Kagaku Ryoho. 1989 Apr;16(4 Pt 2-2):1462-8. Gan To Kagaku Ryoho. 1989. PMID: 2658829 Review. Japanese.
Cited by
-
Long-term culture of human LAK cells.Cytotechnology. 1991 Feb;5(Suppl 1):139-40. doi: 10.1007/BF00736833. Cytotechnology. 1991. PMID: 22358979 No abstract available.
-
Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo.J Exp Med. 1990 May 1;171(5):1527-33. doi: 10.1084/jem.171.5.1527. J Exp Med. 1990. PMID: 2139697 Free PMC article.
-
Role of proliferation in LAK cell development.Cancer Immunol Immunother. 1988;26(2):139-44. doi: 10.1007/BF00205607. Cancer Immunol Immunother. 1988. PMID: 3129192 Free PMC article.
-
Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations.J Neurooncol. 1990 Apr;8(2):173-88. doi: 10.1007/BF00177842. J Neurooncol. 1990. PMID: 2193121 Review.
-
Monocyte-dependent, serum-borne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients.Cancer Immunol Immunother. 1989;29(1):57-62. doi: 10.1007/BF00199917. Cancer Immunol Immunother. 1989. PMID: 2785000 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials